Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Adele Gulfo

Executive Vice President & Chief Strategy Officer at Mylan


Ms. Adele M. Gulfo has been an Executive Vice President of Global Collaboration and Strategic Operations at Mylan, Inc. since January 8, 2014. Ms. Gulfo is Chief Strategy Officer of Mylan N.V. since 2014. Previously, Ms. Gulfo held leadership positions at AstraZeneca Pharmaceuticals, Parke-Davis (Division of Warner-Lambert), SpectraTech Inc., and Fischer Scientific. She served as President of US Primary care business at Pfizer Inc. She served as Vice President of Healthcare Innovation and Corporate Strategy at AstraZeneca PLC. She joined Pfizer from AstraZeneca, where she served as Vice President of Business Development and Design for launch, responsible for sourcing, evaluating and securing external assets including partnerships, acquisitions and licenses, as well as clinical and commercial development across all therapeutic areas of products entering Phase IIb. She serves as Member of Industrial Advisory Board at Cleveland Clinic Innovations. She serves as Regional President, of Latin America in Pfizer's Emerging Markets Business Unit In this capacity, she leads a team of over 4,000 colleagues operating across more than 23 countries. She served as President and General Manager of Pfizer's U.S. Primary Care Business Unit, which included the managed markets (corporate and government customer) organization for all of Pfizer's Biopharmaceutical Business Units. Prior to joining Pfizer, She served as Vice President of Business Development, Innovation and Design for Launch at Astra-Zeneca Pharmaceuticals. She led the multi-billion dollar cardiovascular business, including marketed and emerging products. Among her top achievements, she grew Toprol-XL sales from $200 million to $2 billion and the launched cholesterol-lowering medicine Crestor with a significantly differentiated life-cycle development program, which enabled dramatic growth to over $2 billion in 2009 in a highly competitive market. She served positions of increasing responsibility at Warner-Lambert, including Senior Director of cardiovascular marketing. Prior to launch, She developed the market with award-winning medical and public education that helped to establish the significance of lowering cholesterol in preventing and managing heart disease. Partners included the American Heart Association, the National Institutes of Health and leading academic institutions. She is trained as a scientist with experience in both operational and strategic roles, She serves as a member of the Board of Directors for the Cleveland Clinic's Global Cardiovascular Innovation Center. Ms. Gulfo has been an Independent Director of Bemis Company, Inc. since June 23, 2015. She serves as a Director of Volunteers of America – Greater New York, Inc. She has been awarded five U.S. Patents for innovative packaging designed to help patients adhere to their medicines. She frequently speaks at leading industry and business conferences including The Wall Street Journal's Women in the Economy: An Executive Task Force conference and has been featured in Fortune, Forbes, BusinessWeek and the Wall Street Journal. She is a member of the C200 – the pre-eminent organization of women business leaders, the National Association of Female Executives and the Healthcare Businesswomen's Association's Advisory Board. She is especially proud of receiving the 2012 C200 Luminary Award for Corporate Entrepreneurship. Ms. Gulfo holds a bachelor's degree in Biology and Chemistry from Seton Hall University and a Master of Business Administration degree in Marketing from Fairleigh Dickinson University, both with honors. Ms. Gulfo holds post-graduate in microbiology at the University of Medicine and Dentistry of New Jersey.